Search research articles
Contact Us
Filters
Showing results (111-120 of 117) with videos related to
Page
of 12
Sort By:
You have reached the last page of results.
This site can display upto 117 results.
Clinical Therapeutics
|
November 26, 1998
Evidence that increased calcium intake does not prevent early postmenopausal bone loss
D J Hosking, P D Ross, D E Thompson, et al.
The American Journal of Medicine
|
December 1, 1993
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy
S T Harris, N B Watts, R D Jackson, et al.
The New England Journal of Medicine
|
July 12, 1990
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
N B Watts, S T Harris, H K Genant, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 22, 2000
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group
R P Tonino, P J Meunier, R Emkey, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 19, 2000
Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group
P Ravn, S R Weiss, J A Rodriguez-Portales, et al.
The American Journal of Medicine
|
January 16, 1998
Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment
P D Miller, N B Watts, A A Licata, et al.
Seminars in Arthritis and Rheumatism
|
June 1, 1996
Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry
P D Miller, S L Bonnick, C J Rosen, et al.
Page
of 12
Search research articles
Search
Showing results (111-120 of 117) with videos related to
Sort By:
Page
of 12
You have reached the last page of results.
This site can display upto 117 results.
Clinical Therapeutics
|
November 26, 1998
Evidence that increased calcium intake does not prevent early postmenopausal bone loss
D J Hosking, P D Ross, D E Thompson, et al.
The American Journal of Medicine
|
December 1, 1993
Four-year study of intermittent cyclic etidronate treatment of postmenopausal osteoporosis: three years of blinded therapy followed by one year of open therapy
S T Harris, N B Watts, R D Jackson, et al.
The New England Journal of Medicine
|
July 12, 1990
Intermittent cyclical etidronate treatment of postmenopausal osteoporosis
N B Watts, S T Harris, H K Genant, et al.
The Journal of Clinical Endocrinology and Metabolism
|
September 22, 2000
Skeletal benefits of alendronate: 7-year treatment of postmenopausal osteoporotic women. Phase III Osteoporosis Treatment Study Group
R P Tonino, P J Meunier, R Emkey, et al.
The Journal of Clinical Endocrinology and Metabolism
|
April 19, 2000
Alendronate in early postmenopausal women: effects on bone mass during long-term treatment and after withdrawal. Alendronate Osteoporosis Prevention Study Group
P Ravn, S R Weiss, J A Rodriguez-Portales, et al.
The American Journal of Medicine
|
January 16, 1998
Cyclical etidronate in the treatment of postmenopausal osteoporosis: efficacy and safety after seven years of treatment
P D Miller, N B Watts, A A Licata, et al.
Seminars in Arthritis and Rheumatism
|
June 1, 1996
Clinical utility of bone mass measurements in adults: consensus of an international panel. The Society for Clinical Densitometry
P D Miller, S L Bonnick, C J Rosen, et al.
Page
of 12